Jan 29 |
Looking Into TransCode Therapeutics's Recent Short Interest
|
Jan 29 |
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
|
Jan 22 |
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
|
Jan 19 |
TransCode (RNAZ) Down 50% on Issue of New Common Stock
|
Jan 19 |
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
|
Jan 18 |
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
|
Jan 12 |
TransCode Therapeutics announces retirement of CEO
|
Jan 12 |
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
|
Jan 11 |
TransCode Therapeutics announces 1-for-40 reverse stock split
|
Jan 11 |
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
|